Patient Education: Isatuximab-irfc - Sarclisa - Monoclonal Antibody - Immunotherapy
- Patient Education
- Dec 6, 2022
- 1 min read
Updated: Jan 27, 2024
Patient Education: Isatuximab-irfc - Sarclisa - Monoclonal Antibody - Immunotherapy
ISATUXIMAB-IRFC (SARCLISA)
NIH National cancer institute - cancer.gov site info
This page contains brief information and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
US Brand Name(s): Sarclisa
FDA Approved: Yes
MedlinePlus Information
A lay language summary of important information about this drug that may include the following:
warnings about this drug,
what this drug is used for and how it is used,
what you should tell your doctor before using this drug,
what you should know about this drug before using it,
other drugs that may interact with this drug, and
possible side effects.
Information on Sarclisa website
INTERNATIONAL MYELOMA FOUNDATION:
Understanding SARCLISA (isatuximab-irfc)
IMF Understanding Series
IMF Resource Library
Current FDA-Approved Medications for Multiple Myeloma Treatment
HEALTH TREE UNIVERSITY MYELOMA:
All About Sarclisa (Isatuximab)
HealthTree University for Multiple Myeloma Lectures
HealthTree University Myeloma Videos
MULTIPLE MYELOMA RESERACH FOUNDATION:
Standard Treatments - Sarclisa, Isatuximab (SAR650984) Anti-CD38 monoclonal antibody
MMRF Education Programs
MMRF Videos
References Sarclisa:
FDA Label Prescribing Information (Revised 03/2021)
Drug Label Information at DAILYMED - NIH-National Library of Medicine
Other Resources
- Multiple Myeloma Patient Education & Information on ongoing Multiple Myeloma Clinical Trials -
* Belantamab mafodotin (Withdrawn from United States market)